Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection

Abstract

Patients with symptomatic HIV infection, including AIDS and ARC are treated to increase appetite and to cause a reduction in loss of weight. The delta-9-tetrahydrocannabinol may be administered orally, in capsules, or in tablets, or by injection, suppository, intranasal, transdermal, inhalant or sublingual administration.

What is claimed is:  
     
         1 . Method of treating patients with symptomatic HIV infection to provide improved appetite and a reduction in loss of stimulating reduction in loss of weight effective amount of delta-9-tetrahydrocannabinol, thereby obtaining improved appetite and a reduction in loss of weight.  
     
     
         2 . Method according to  claim 1  wherein said administration is orally.  
     
     
         3 . Method according to  claim 1  wherein said delta-9-tetrahydrocannabinol is administered in dosages between about 2.5 mg to 20 mg daily in single or divided doses.  
     
     
         4 . Method according to  claim 1  wherein said delta-9-tetrahydrocannabinol is administered in the form of capsules containing said delta-9-tetrahydrocannabinol in sesame oil.  
     
     
         5 . Method according to  claim 1 , wherein said HIV infection is AIDS.  
     
     
         6 . Method according to  claim 5 , wherein said administration is hrall5.  
     
     
         7 . Method according to  claim 5 , wherein said delta-9-tetrahydrocannabinol is administered in dosages between about 2.5 mg to 20 mg daily in single or divided doses.  
     
     
         8 . Method according to  claim 5 , wherein said delta-9-tetrahydrocannabinol is administered in the form of capsules containing said delta-9-tetrahydrocannabinol in sesame oil.  
     
     
         9 . Method according to  claim 1 , wherein said HIV infection is ARC.  
     
     
         10 . Method according  claim 9 , wherein said administration is orally.  
     
     
         11 . Method according  claim 9 , wherein said delta-9-tetrahydrocannabinol is administered in dosages between about 2.5 mg to 20 mg daily in single or divided doses.  
     
     
         12 . Method according to  claim 9 , wherein said delta-9-tetrahydrocannabinol is administered in the form of capsules containing said delta-9-tetrahydrocannabinol in sesame oil.